What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The clinical effectiveness of ruxolitinib is supported by the REACH2 trial, a Phase 3 randomized controlled trial that demonstrated a higher overall response rate at day 28 (62.3% vs. 39.4%) compared to standard care. Additionally, ruxolitinib showed longer failure-free survival, although the committee noted concerns regarding the trial’s open-label design and potential biases in treatment switching.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for ruxolitinib were deemed acceptable by NICE, falling within the range considered a cost-effective use of Healthcare resources. The committee noted that the most plausible ICER was towards the lower end of the acceptable range, indicating a defensible economic value.
Is there quality-of-life evidence payers weigh? — Quality of life
While specific HRQoL data were not extensively detailed, the committee acknowledged that ruxolitinib’s oral administration could improve quality of life by reducing the need for hospital visits and invasive procedures, which is particularly beneficial for patients with acute GvHD. However, the evidence for sustained HRQoL improvements was not robustly quantified.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ruxolitinib was reported to have a very good safety profile, with mostly mild to moderate adverse events. The committee noted that the treatment’s tolerability was comparable to existing therapies, with rare serious adverse events, supporting a favorable safety assessment.
Was the drug compared against what payers expect? — Comparator Selection
The REACH2 trial compared ruxolitinib to standard care, which included various treatments. However, the committee expressed concerns about the representativeness of the standard care arm, as it may not fully reflect Healthcare practice, particularly regarding the use of extracorporeal photopheresis (ECP).
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included individuals aged 12 years and older with corticosteroid-refractory acute GvHD, which aligns with the marketing authorization. The committee found the evidence generalizable to young people and noted the importance of addressing the unmet need in this population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ruxolitinib can be integrated into existing care pathways with minimal adjustments, as it is an oral treatment that can be administered at home. This reduces the burden on healthcare facilities and aligns well with current clinical practices for managing acute GvHD.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicated that ruxolitinib would have a manageable budget impact, with the potential for net savings due to reduced hospital visits and associated costs. The committee acknowledged the importance of considering broader resource implications in the economic evaluation.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is primarily derived from the REACH2 trial, a Phase 3 RCT, which provides a strong foundation for the evaluation. However, the committee noted some methodological concerns, particularly regarding the open-label design and potential biases.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
The committee identified significant uncertainties related to the open-label design of the trials and the assumptions made in the economic model. While the overall context supports ruxolitinib’s use, these uncertainties could impact decision-making and require careful consideration.
